NYC-WTC_000195068

NYC 9/11 Public Portal Document

ASBESTOS MEDITEXT ® - Medical Management Page 2 of 17

20. Barris YI, Bilir N, Artvinli M et al: An epidemiological study in an Anatolian village environmentally exposed to tremolite asbestos. Br J Ind Med 1988; 45:838-840. 21. Becklake MB: Asbestos and other fiber-related diseases of the lungs and pleura. Chest 1991; 1:248-254. 22. Berry G, Newhouse ML & Antonis P: Combined effect of asbestos and smoking on mortality from lung cancer and mesothelioma in factory workers. Br J Ind Med 1985; 42:12-18. 23. Berry M: Mesothelioma incidence and community asbestos exposure. Environ Res 1997; 75:34-40. 24. Bianchi C, Brollo A, Ramani L et al: Asbestos exposure in lung carcinoma: a necropsy-based study of 414 cases. Am J Ind Med 1999; 36:360-364. 25. Bianchi C, Brollo A, Ramani L et al: Pleural plaques as risk indicators for malignant pleural mesothelioma: a necropsy-based study. Am J Ind Med 1997; 32:445-449. 26. Bissonnette E, Carre B, Dubois C et al: Inhibition of alveolar macrophage cytotoxicity by asbestos: possible role of prostaglandin. J Leukoc Biol 1990; 47:129-134. 27. Blanc PD, Golden JA, Gamsu G et al: Asbestos exposure - cigarette smoking interactions among shipyard workers. JAMA 1988; 259:370-373. 28. Boffetta P, Stellman SD & Garfinkel L: A case-control study of multiple myeloma nested in the American Cancer Society prospective study. Intemat J Cancer 1989; 43:554-559. 29. Both K, Henderson DW & Turner DR: Asbestos and erionite fibres can induce mutations in human lymphocytes that result in loss of heterozygosity. Intemat J Cancer 1994; 59:538-542. 30. Bravo MP, Del Rey Calero J & Conde M: Bladder cancer and asbestos in Spain. Rev Epidemiol Sante Publique 1988; 36:10-14. 31. Brody AR: Asbestos-induced lung disease. Environ Health Perspect 1993; 100:21-30. 32. Brown LM, Mason TJ, Pickle LW et al: Occupational risk factors for laryngeal cancer on the Texas Gulf Coast. Cancer Res 1988; 48:1960-1964. 33. Brown RC, Carthew P, Hoskins JA et al: Surface modification can affect the carcinogenicity of asbestos. Carcinogenesis 1990; 11:1883-1885. 34. Browne K: Asbestos-related mesothelioma: epidemiological evidence for asbestos as a promoter. Arch Environ Health 1983; 5:261-266. 35. Browne K: Br J Ind Med 1986; 43:556-558. 36. Budavari S (Ed): The Merck Index, 11th ed. Merck & Co, Inc, Rahway, NJ, 1989. 37. Budavari S (Ed): The Merck Index, 12th ed. Merck & Co, Inc, Whitehouse Station, NJ, 1996. 38. Callahan KS, Griffith DE & Garcia JGN: Asbestos exposure results in increased lung procoagulant activity in vivo and in vitro. Chest 1990; 98:112-119. 39. Casey G: Sister-chromatid exchange and cell kinetics in CHO-Kl cells, human fibroblasts and lymphoblastoid cells exposed in vitro to asbestos and glass fibre. Mutat Res 1983; 116:369- 377. 40. Cavalieri A, Gobba F, Bacchella L et al: Serum type HI procollagen peptide in asbestos workers: an early indicator of pulmonary fibrosis. Br J Ind Med 1988; 45:818-823. 41. Chamberlain M & Tarmy EM: Asbestos and glass fibres in bacterial mutation tests. Mutat Res 1977;43:159-164. 42. Chang LY, Overby LH, Brody AR et al: Progressive lung cell reactions and extracellular matrix production after a brief exposure to asbestos. Am J Pathol 1988; 131:156-170. 43. Chemsoft(R): Electronic EPA, NIOSH, & OSHA Methods(TM). Windowchem(TM) Software, Fairfiled, CA, 1996. 44. CHRIS: CHRIS Hazardous Chemical Data. US Department of Transportation, US Coast Guard, Washington, DC (CD-ROM Version), Micromedex, Inc, Englewood, CO, 1990. 45. CHRIS: CHRIS Hazardous Chemical Data. US Department of Transportation, US Coast Guard, Washington, DC (CD-ROM Version), Micromedex, Inc, Englewood, CO, 1992. 46. CHRIS: CHRIS Hazardous Chemical Data. US Department of Transportation, US Coast

http://www.tomescps.com/DATA/TM/TM356-c.htm 1/4/2002

CITY_21MC100_011105085

NYC-WTC_000195103